Cochrane · systematic review · CD006044
Lamotrigine for chronic neuropathic pain and fibromyalgia in adults
Wiffen, PJ, Derry, S, Moore, RA · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 40%Low 0 · 0%Moderate 1 · 20%High 2 · 40%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Lamotrigine 200 to 400 mg versus placebo for neuropathic pain
Population: neuropathic pain (three studies in painful diabetic neuropathy)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 50% of maximum pain relief Lamotrigine 200 to 400 mg vs placebo | no estimate extracted | NR | High |
Participants with at least 1 adverse event (all conditions) Lamotrigine 200 to 400 mg vs placebo | no estimate extracted | NR | High |
Participants with a serious adverse event (all conditions) Lamotrigine 200 to 400 mg vs placebo | no estimate extracted | NR | Very low |
Participants with rash (all conditions) Lamotrigine 200 to 400 mg vs placebo | no estimate extracted | NR | Moderate |
Deaths (all conditions) Lamotrigine 200 to 400 mg vs placebo | no estimate extracted | NR | Very low |